Gerald Edelman is delighted to announce that its Corporate Finance team has successfully advised the shareholders of Blackberry Clinic Group Limited (“Blackberry Clinic”) on its acquisition by the renowned international healthcare group, Bupa.

Established in 1988, Blackberry Clinic has earned international recognition for its expertise in treating sports injuries, as well as back, muscle, and joint ailments. With a dedicated team comprising specialist doctors, physiotherapists, osteopaths, and chiropractors, the clinic has played a pivotal role in supporting elite athletes, including international footballers competing in the World Cup and British rowers securing Olympic Gold medals.

Under the stewardship of CEO, David Eades, Blackberry Clinic has expanded its service offering over the last two decades, notably with the introduction of Bupa Health Assessments. This strategic partnership has fueled Blackberry Clinic’s growth, resulting in the establishment of eleven new clinics since 2022, bringing its total footprint to twenty-two medical clinics across the UK.

The acquisition marks a significant milestone for both Blackberry Clinic and Bupa, reaffirming their commitment to delivering high-quality healthcare services, and providing Bupa with more direct access to customers. Pricing and other deal terms have not been disclosed.

Blackberry Clinic was also advised by Memery Crystal (legal).

Simon Petrides, Medical Director and shareholder, commented:

The Gerald Edelman team worked tirelessly to ensure the successful completion of the deal within a short timeframe, providing invaluable support throughout the process. Their expertise in navigating and negotiating the complexities of the financial and commercial elements of the transaction was particularly appreciated, contributing to what was a highly successful exit for all shareholders.

Sam Barr, Associate Director, in Gerald Edelman’s Corporate Finance team, added:

We are extremely proud to have advised the shareholders of Blackberry Clinic on this transaction. It has been a pleasure working with Simon, Kate, and David throughout the process.

This deal signifies yet another achievement for our Corporate Finance team, marking our second healthcare transaction in two months, and our third completed deal in the same period. It reflects our dedication to delivering exceptional results for our clients and highlights continued momentum in the lower mid-market M&A landscape, which we expect to see continue in 2024. We wish all parties every success for the future!